Sarda Proteins

Is Sarda Proteins overvalued or undervalued?

As of January 6, 2025, Sarda Proteins Ltd. is considered overvalued with a "risky" rating due to high financial ratios, including a PE Ratio of 22.60 and a Price to Book Value of 9.54, despite a strong 1-year return of 62.51%.

As of 6 January 2025, Sarda Proteins Ltd. has moved from a grade of "does not qualify" to "risky," indicating a shift in its valuation outlook. The company appears to be overvalued based on its current financial ratios. The PE Ratio stands at 22.60, while the Price to Book Value is significantly high at 9.54, and the EV to Sales ratio is 21.29, all suggesting that the stock price may not be justified by its earnings or asset value.<BR><BR>In comparison to its peers, Sarda Proteins' PE ratio is higher than the industry average, which raises concerns about its valuation. Notably, its EV to EBITDA is -22.57, indicating negative earnings before interest, taxes, depreciation, and amortization, which is a significant red flag. While the company has outperformed the Sensex with a 1-year return of 62.51% compared to the Sensex's 7.57%, this performance may not be sustainable given the current valuation metrics. Overall, Sarda Proteins appears to be overvalued in the current market environment.

What is the technical trend for Sarda Proteins?

As of May 20, 2025, Sarda Proteins shows a mildly bullish trend with mixed signals from indicators like the MACD, Bollinger Bands, and RSI, suggesting caution despite the current price being at a 52-week high of 137.45.

As of 20 May 2025, the technical trend for Sarda Proteins has changed from bullish to mildly bullish. The weekly MACD and Bollinger Bands indicate a bullish stance, while the monthly RSI shows bearish momentum. Daily moving averages remain bullish, supporting the current price of 137.45, which is at a 52-week high. The KST is mildly bearish on a weekly basis but bullish monthly, and Dow Theory reflects a mildly bullish outlook in both time frames. Overall, the strength of the bullish trend is tempered by mixed signals in the RSI and KST, suggesting caution despite the positive indicators.

How has been the historical performance of Sarda Proteins?

Sarda Proteins has shown significant sales growth, with net sales rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, but faced challenges with increased expenditures, resulting in marginal operating profit and a decrease in profit after tax and EPS. Overall, while sales and total assets have grown, profitability remains a concern.

Answer:<BR>The historical performance of Sarda Proteins shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Sarda Proteins experienced a notable increase in net sales, rising from 1.30 Cr in Mar'24 to 24.19 Cr in Mar'25, following a trend of varying sales figures over the previous years. The total operating income also reflected this growth, reaching 24.19 Cr in Mar'25 compared to 1.30 Cr in the prior year. However, the company faced challenges with total expenditure, which increased to 24.17 Cr in Mar'25 from 1.44 Cr in Mar'24. This resulted in a marginal operating profit of 0.02 Cr in Mar'25, a slight improvement from the losses recorded in earlier years. The profit before tax remained stable at 0.02 Cr for both Mar'25 and Mar'24, while profit after tax showed a decrease to 0.01 Cr in Mar'25 from 0.02 Cr in Mar'24. The earnings per share (EPS) also reflected this trend, decreasing to 0.06 in Mar'25 from 0.12 in Mar'24. On the balance sheet, total assets increased to 2.53 Cr in Mar'25 from 2.30 Cr in Mar'24, driven by a rise in short-term loans and advances. Overall, while Sarda Proteins has shown growth in sales and total assets, profitability metrics indicate ongoing challenges.

Should I buy, sell or hold Sarda Proteins?

When is the next results date for Sarda Proteins Ltd?

The next results date for Sarda Proteins Ltd is 14 February 2026.

The next results date for Sarda Proteins Ltd is scheduled for 14 February 2026.

Why is Sarda Proteins Ltd falling/rising?

As of 12-Feb, Sarda Proteins Ltd's stock price is Rs 71.00, down 4.05%, and has underperformed the Sensex. The stock has seen a total decline of 8.51% over the last three days, indicating a bearish trend and reduced investor participation.

As of 12-Feb, Sarda Proteins Ltd's stock price is falling, currently at Rs 71.00, which represents a decrease of Rs 3.0 or 4.05%. The stock has underperformed compared to the benchmark Sensex, which has gained 0.43% over the past week, while Sarda Proteins Ltd has declined by 3.96% in the same period. Additionally, the stock has experienced a consecutive fall over the last three days, resulting in a total decline of 8.51% during this timeframe.<BR><BR>Today's trading session began with the stock opening down by 4.05%, and it has not traded above this opening price, indicating a lack of upward momentum. The stock also touched an intraday low of Rs 71, reflecting ongoing selling pressure. Furthermore, the stock's delivery volume has decreased by 8.52% compared to the five-day average, suggesting a decline in investor participation.<BR><BR>While the stock remains above its 200-day moving average, it is below its shorter-term moving averages (5-day, 20-day, 50-day, and 100-day), indicating a bearish trend in the short term. Overall, these factors contribute to the stock's current downward trajectory.

Which are the latest news on Sarda Proteins?